Trial Profile

A clinical study of a replication-competent, recombinant herpes simplex virus type 1 (G47delta) in patients with progressive glioblastoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 30 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teserpaturev (Primary)
Indications Glioblastoma
Focus Adverse reactions; First in man

Most Recent Events

21 Jul 2022 Results assessing the safety (primary endpoint) of G47 delta, a triple-mutated oncolytic herpes simplex virus type 1, in Japanese adults with recurrent/progressive glioblastoma despite radiation and temozolomide therapies published in the nature communications
24 Jun 2021 New trial record
05 Jun 2021 According to a Daiichi Sankyo Company media release, this trial were conducted by Dr. Todo at the University of Tokyo.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com